Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis - Related Studies

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

This study is currently recruiting participants.

Study NCT00586651. Last updated on June 24, 2008. Information provided by Cephalon

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Polycythemia Vera
		Essential Thrombocytosis

2	Additional conditions recognized in this trial
		Polycythemia
		Thrombocythemia, Hemorrhagic
		Thrombocytosis

3	More general conditions related to this trial
		Blood Coagulation Disorders
		Blood Platelet Disorders
		Bone Marrow Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Myeloproliferative Disorders

4	Interventions listed in this trial
		lestaurtinib

5	Sponsors listed in this trial
		Cephalon